239 related articles for article (PubMed ID: 30248571)
1. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
[TBL] [Abstract][Full Text] [Related]
2. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
Fragomeni MO; Bichuetti DB; Oliveira EML
Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
[TBL] [Abstract][Full Text] [Related]
3. Early versus later treatment start in multiple sclerosis: a register-based cohort study.
Chalmer TA; Baggesen LM; Nørgaard M; Koch-Henriksen N; Magyari M; Sorensen PS;
Eur J Neurol; 2018 Oct; 25(10):1262-e110. PubMed ID: 29847005
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.
Spelman T; Frisell T; Piehl F; Hillert J
Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C
Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667
[TBL] [Abstract][Full Text] [Related]
7. Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.
Moccia M; Santoni L; Vaccari I; Affinito G; Caliendo D; Rubba F; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):411-418. PubMed ID: 38235893
[TBL] [Abstract][Full Text] [Related]
8. Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.
Signori A; Gallo F; Bovis F; Di Tullio N; Maietta I; Sormani MP
Mult Scler Relat Disord; 2016 Mar; 6():57-63. PubMed ID: 27063624
[TBL] [Abstract][Full Text] [Related]
9. Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Jokubaitis VG; Spelman T; Kalincik T; Lorscheider J; Havrdova E; Horakova D; Duquette P; Girard M; Prat A; Izquierdo G; Grammond P; Van Pesch V; Pucci E; Grand'Maison F; Hupperts R; Granella F; Sola P; Bergamaschi R; Iuliano G; Spitaleri D; Boz C; Hodgkinson S; Olascoaga J; Verheul F; McCombe P; Petersen T; Rozsa C; Lechner-Scott J; Saladino ML; Farina D; Iaffaldano P; Paolicelli D; Butzkueven H; Lugaresi A; Trojano M;
Ann Neurol; 2016 Jul; 80(1):89-100. PubMed ID: 27145331
[TBL] [Abstract][Full Text] [Related]
10. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
Duddy M; Palace J
Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
[No Abstract] [Full Text] [Related]
11. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
Palace J; Duddy M; Lawton M; Bregenzer T; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Lilford R; Dobson C
J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):251-260. PubMed ID: 30242090
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
Mahurkar S; Suppiah V; O'Doherty C
Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
[TBL] [Abstract][Full Text] [Related]
13. A non-parametric propensity score for estimating the effect of interferon-beta or glatiramer acetate on long-term outcomes of multiple sclerosis.
Mésidor M; Sylvestre MP; Rousseau MC; Roger E; Duquette P
Mult Scler Relat Disord; 2021 Aug; 53():103050. PubMed ID: 34116479
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
Lublin FD; Cofield SS; Cutter GR; Gustafson T; Krieger S; Narayana PA; Nelson F; Salter AR; Wolinsky JS
Mult Scler Relat Disord; 2017 Nov; 18():95-102. PubMed ID: 29141831
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.
Armoiry X; Kan A; Melendez-Torres GJ; Court R; Sutcliffe P; Auguste P; Madan J; Counsell C; Clarke A
J Neurol; 2018 May; 265(5):999-1009. PubMed ID: 29356977
[TBL] [Abstract][Full Text] [Related]
17. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
18. Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study.
Drulovic J; Ivanovic J; Mesaros S; Martinovic V; Kisic-Tepavcevic D; Dujmovic I; Pekmezovic T
Neurol Sci; 2019 Aug; 40(8):1627-1636. PubMed ID: 31011930
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis.
Velazquez-Villoria D; Macia-Badia C; Segura-García A; Pastor Idoate S; Arcos-Algaba G; Velez-Escola L; García-Arumí J
Arch Soc Esp Oftalmol; 2017 Jun; 92(6):273-279. PubMed ID: 28188020
[TBL] [Abstract][Full Text] [Related]
20. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
